交联可调式抗结核药物缓释型纳米人工骨体内成骨的观察  

Osteogenetic capacity of cross-linked adjustable anti.tuberculosis drug sustained-release artificial composite

作　　者：席焱海 薛敏涛 叶晓健 徐宁 瞿金涛 刘希麟 何海龙 

机构地区：[1]第二军医大学第二附属医院骨科医院脊柱外科,上海200003

出　　处：《中华医学杂志》2013年第19期1494-1498,共5页National Medical Journal of China

基　　金：上海市科委纳米专项基金（12nm0501202,1052nm03203）

摘　　要：目的观察新型复合材料交联可调式抗结核药物缓释型纳米人工骨复合体（TPB／SARFP／PLA）的成骨效能。方法建立兔股骨骨缺损模型，将TPB／SA—RFP／PLA复合体作为实验组（A组），缺损区填入TPB／SA／PLA材料作为对照组（B组），缺损区不做处理作为空白对照组（c组）。分别在术后4、8、12周进行取材，对大体标本进行X线扫描、固定后组织染色和免疫组化定性分析，进而确定交联抗结核药的人工骨复合体的体内成骨性能。结果大体及组织学观察和X线显示TPB／SA—RFP／PLA复合体同对照组相比较有着良好的成骨效能。同TPB／SA／PLA组比较成骨效能无明显差别。lane—sandhu组织学评分：A组（7．5±0．5）分、B组（7．2±0．3）分、C组（2．5±0．4）分。lane—sandhuX线评分术后12周：A组（8．3±0．3）分、B组（8．6±0．2）分、C组（2．2±0．4）分。TPB／SA—RFP／PLA材料组与空白对照组差异有统计学意义（P〈0．05），与TPB／SA／PLA材料组问差异无统计学意义（P〉0．05）。免疫组化结果显示两组材料组ALP染色呈强阳性，对照组呈弱阳性。结论复合材料TPB／SA-RFP／PLA具有很好的骨传导性和骨再生能力，复合利福平抗结核药物后不影响复合材料的体内成骨能力。Objective To explore the osteogenetic capacity of cross-linked adjustable antituberculosis drug sustained-release artificial composite （TPB/SA-RFP/PLA）. Methods The model of femur bone defect was established in rabbits. TPB/SA-RFP/PLA complex was implanted into defect parts in the experimental group while TPB/SA/PLA in the blank control group. At Weeks 4, 8 and 12, gross specimens received radiographic, histological and immunohistochemical examinations to determine the osteogenetic performance of TPB/SA-RFP/PLA. Results As compared with the control group, TPB/SA- RFP/PLA complex had excellent osteogenie capacities while the TPB/SA/PLA group had no obvious osteogenic difference. Lane-sandhu histological and radiographic ratings demonstrated significant difference between TPB/SA-RFP/PLA （8.3 ± 0. 3 ） and blank groups （2.2 ± 0.4 ） （P 〈 0.05 ）. And TPB/SA/PLA showed no significant intragroup significance （P 〉 0. 05 ） . Two groups immunohistochemical Alkaline phosphatase was strongly positive in two test groups and weakly positive in the control group. Conclusion TPB/ SA-RFP/PLA has excellent profiles of bone conductivity and regeneration. And the incorporation of rifapin does not affect its osteogenetic capacity.

关 键 词：利福平 迟效制剂 成骨不全 纳米 

分 类 号：R6[医药卫生—外科学] R3[医药卫生—临床医学]